Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Pedro Moura Alves secures funding to screen for drugs that regulate aryl hydrocarbon receptor (AHR) activity.

The AHR is an important cellular sensor that recognises a large number of molecules to enable the cell to respond appropriately to different environmental triggers. Recent research has revealed the AHR’s involvement in the pathology of several diseases, including cancer, infectious diseases and neurological disorders. There is now a great interest in trying to identify drugs that can modulate AHR activity and potentially be repurposed for treatment of these diseases.

Ludwig Oxford’s Dr Pedro Moura Alves has been awarded money from the University of Oxford’s John Fell Fund to carry out a systematic screen for AHR regulators. In collaboration with Dr Daniel Ebner’s High Throughput Screening Facility (Target Discovery Institute), Pedro will use several AHR reporter cell lines and libraries of existing drugs to identify molecules that regulate AHR activity. These hits will undergo further validation, including work in zebrafish larvae which are a good model for assessing responses to molecules in the context of a whole organism. It is hoped that this work will reveal both novel therapeutic strategies for AHR-linked diseases and new information about the regulation of AHR that will guide future research.

Similar stories

Ludwig Oxford retreat 2022 – a recap

On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.